# A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

> **NCT03191773** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Lymphoma

## Interventions

- **COMBINATION_PRODUCT:** Drugs and anti-CD19 CAR transduced T cells

## Key facts

- **NCT ID:** NCT03191773
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-30
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-06-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03191773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03191773, "A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03191773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*